Pfizer has signed an agreement to collaborate with the National Cancer Institute’s (NCI) Center for Cancer Research (CCR) to arrange and conduct preclinical and clinical trials in a bid to assess three investigational immunotherapy agents.
Under the cooperative research and development agreement (CRADA), Pfizer’s trials will include immunotherapy agonistic monoclonal antibodies targeting OX40 (CD134); utomilumab, targeting 4-1BB (CD137) and avelumab, a fully human anti-PD-L1 IgG1 monoclonal antibody.
Avelumab is being developed by the company through an alliance between Merck and Pfizer.
The three agents will be studied in various combinations and in combination with standard therapies, such as chemotherapy, radiation and targeted therapies across a range of cancers.
Pfizer global product development immuno-oncology, translational oncology and early development senior vice-president and head Dr Chris Boshoff said: “We are looking forward to combining our expertise with those at the NCI to explore agents targeting the immune system in doublet and triplet combinations.
“The CRADA is an important collaboration for us as we seek to realise the full potential of immunotherapy and hope to ultimately transform the cancer treatment paradigm.”
Pfizer has individually announced it will meet humanitarian emergency needs through a short-term donation of the single-dose vial of Prevenar 13 vaccine.
Beginning next year, refugees can receive the newest version of Prevenar 13, the multi-dose vial (MDV), which is specially designed to address the unique conditions and challenges experienced in developing world settings.
It offers reduced cold storage and transportation requirements and helps to quickly enable the vaccination of children in humanitarian emergency situations.